Compare TKNO & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TKNO | MOLN |
|---|---|---|
| Founded | 1996 | 2004 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 280.9M | 143.3M |
| IPO Year | 2021 | 2021 |
| Metric | TKNO | MOLN |
|---|---|---|
| Price | $4.76 | $3.81 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $8.38 |
| AVG Volume (30 Days) | ★ 238.2K | 4.4K |
| Earning Date | 05-06-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 43.86 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $40,520,000.00 | N/A |
| Revenue This Year | $8.27 | N/A |
| Revenue Next Year | $13.13 | $374.07 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 7.35 | N/A |
| 52 Week Low | $1.91 | $3.41 |
| 52 Week High | $6.68 | $5.36 |
| Indicator | TKNO | MOLN |
|---|---|---|
| Relative Strength Index (RSI) | 54.91 | 45.38 |
| Support Level | $4.09 | $3.61 |
| Resistance Level | $4.94 | $4.01 |
| Average True Range (ATR) | 0.47 | 0.13 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 41.95 | 31.11 |
Alpha Teknova Inc is a producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics. Its offer two primary product categories: Lab Essentials and Clinical Solutions. It derives key revenue from the United States. The company offers three primary product types: (i) pre-poured media plates for cell growth and cloning; (ii) liquid microbial culture media and supplements for cellular expansion; and (iii) molecular biology reagents for sample manipulation, resuspension, and purification.
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company is currently focusing on oncology through their robust pipeline of clinical and preclinical programs, with particular attention to MP0712, the key Radio-DARPin candidate targeting DLL3 now in a Phase 1/2a trial in the United States.